Breakthrough Treatment Helps Prolong Life for People with Metastatic Lung Cancer

September 26, 2018—(BRONX, NY)—When lung cancer has spread, or metastasized, to other parts of the body, standard chemotherapy offers only a modest survival benefit. Now, in a major advance described in today’s issue of theNew England Journal of Medicine, an international team, including researchers from Albert Einstein College of Medicine and Montefiore Health System, report that combining chemotherapy with the immunotherapy drug Keytruda extends the lives of people with metastatic squamous non-small cell lung cancer (NSCLC) by more than 40 percent compared with chemotherapy alone—a significant improvement that should immediately change the standard of care.
Source: Einstein News - Category: Universities & Medical Training Source Type: news